MGI, a member of global genomics leader BGI Group, has expanded its DNA sequencing and laboratory automation products available in Latin America, signing agreements with top distributors in Brazil, Argentina, Peru, Ecuador, Colombia and Mexico.
Through these experienced partners, MGI will be able to immediately offer its products for the research, clinical/diagnostics and other markets. Distributors have acquired MGI sequencers and other instruments to offer local demonstrations and training sessions for potential customers. Commercial partners will provide pre-sale, sales, application support and after-sales service support. MGI’s own commercial team in the LATAM region, including regional sales managers, field scientists and field engineers, will support all direct and indirect activities to ensure success.
MGI is pleased to announce it has signed distribution partnerships with Datamed (Brazil), Lobov (Argentina), Kossodo (Peru), RecordQ (Ecuador), Gencell Pharma (Colombia) and Quimica Valaner (Mexico).
“Our channel partners and distributors bring decades of experience in the importation and commercialization of laboratory instrumentation and reagents, combined with experience introducing molecular and genetic testing products into these markets and knowledge of local customer needs,” said Carlos M. Carpio MSc, Commercial Director, LATAM for MGI. In line with its strong growth, MGI is actively interviewing additional distributor candidates for the region, he said.
As an example of rapid early adoption of MGI technology in Latin America, three laboratories have recently acquired MGI instruments:
· Biogenar– Precision Medicine (Argentina) purchased the MGISEQ-2000RS high-throughput sequencer and MGISP-100 library preparation system.
· Gencell Pharma(Molecular Genetics Laboratory) in Colombia also purchased the MGISEQ-2000RS high-throughput sequencer, MGISP-100 library preparation system and an automatic flow cell loader MGIDL-200RS.
· Oswaldo Cruz Foundation (Fiocruz) of Brazil, which has partnered with MGI on scientific cooperation,received the DNBSEQ-G400RS (MGISEQ-2000RS) and DNBSEQ-G50RS (MGISEQ-200RS) high-throughput sequencers.
MGI’s core DNBSEQTM sequencing technology combines low error accumulation, low duplicate reads and high signal intensity, which can improve accuracy and efficiency.
MGI Tech Co., Ltd. (MGI), a member of global genomics leader BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on R&D, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, mass spectrometry, medical imaging and laboratory automation.